Hypofractionated radiation has become the preferred treatment for various types of cancer, offering higher doses in fewer sessions compared to conventional therapy. Despite evidence supporting its effectiveness and safety, many patients do not receive this treatment option due to reimbursement challenges. Studies have shown that hypofractionation may be more cost-effective and convenient for patients and physicians. Efforts are underway to change reimbursement models to encourage wider adoption of hypofractionation in radiation oncology practices, particularly in smaller community settings. Legislation is being considered in Congress to shift Medicare reimbursements to a per-patient, per-disease model to address these financial barriers.
Source link
Despite Strong Data, Hypofractionated Radiation Underused
